Vimta Labs Limited — Updates, 17-07-2025: Press Release

Vimta Labs delivered strong Q1 FY26 results, with Total Income jumping 31.4% YoY to Rs. 99.3 Cr, fueled by pharmaceutical & food contract research. Profit After Tax (PAT) grew 35.9% YoY to Rs. 18.9 Cr, maintaining robust EBITDA margins at 35.7%. Operationally, Vimta achieved a USFDA inspection with zero Form 483 observations and received EMA cGMP compliance, highlighting its quality commitment. Further boosting shareholder value, the Board approved a 1:1 bonus issue, signaling financial strength and confidence in future growth.